Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

Rheumatoid arthritis (RA) is a chronic disease with autoimmune traits of unknown aetiology which primarily affects synovial joints. Glucocorticoids (GCs) are still widely used in RA treatment despite the expanding use of targeted and very efficient agents. The objective of this study was to assess the impact of treatment with tumour necrosis factor-α inhibitors (TNFi) on GC utilization in real-life practice among Danish RA patients.
Original languageEnglish
JournalDanish Medical Bulletin
Volume58
Issue number4
Pages (from-to)A4257
ISSN0907-8916
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Tumour necrosis factor-α inhibitors are glucocorticoid-sparing in rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this